These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
799 related items for PubMed ID: 24283206
21. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB. J Clin Oncol; 2012 Oct 01; 30(28):3460-7. PubMed ID: 22665537 [Abstract] [Full Text] [Related]
23. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Marcheselli L, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M. Br J Haematol; 2015 May 01; 169(4):544-51. PubMed ID: 25817296 [Abstract] [Full Text] [Related]
25. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB. Ann Hematol; 2013 Nov 01; 92(11):1513-20. PubMed ID: 23775580 [Abstract] [Full Text] [Related]
26. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y. Leuk Res; 2013 Oct 01; 37(10):1208-12. PubMed ID: 23927994 [Abstract] [Full Text] [Related]
27. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. Yamamoto M, Watanabe K, Fukuda T, Miura O. Anticancer Res; 2017 May 01; 37(5):2655-2662. PubMed ID: 28476841 [Abstract] [Full Text] [Related]
28. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma. Lee HS, Park LC, Lee EM, Shin SH, Ye BJ, Oh SY, Song MK, Lee SM, Lee WS, Kang BW, Chang MH, Cho SG, Yahng SA, Yoon SS, Kwon JH, Kim YS. Am J Clin Oncol; 2014 Apr 01; 37(2):182-7. PubMed ID: 23211226 [Abstract] [Full Text] [Related]
31. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F. Ann Hematol; 2018 Jun 01; 97(6):1009-1018. PubMed ID: 29442162 [Abstract] [Full Text] [Related]
39. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. Niitsu N, Tamaru J, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Okamoto M. Ann Hematol; 2011 Feb 01; 90(2):185-92. PubMed ID: 20809421 [Abstract] [Full Text] [Related]